LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 22

Search options

  1. Article ; Online: Chloroquine or Hydroxychloroquine for COVID-19: Is Cardiotoxicity a Concern?

    Kamp, Timothy J / Hamdan, Mohamed H / January, Craig T

    Journal of the American Heart Association

    2020  Volume 9, Issue 12, Page(s) e016887

    MeSH term(s) Betacoronavirus ; COVID-19 ; Cardiotoxicity ; Chloroquine/adverse effects ; Chloroquine/therapeutic use ; Coronavirus Infections/drug therapy ; Coronavirus Infections/epidemiology ; Global Health ; Heart Diseases/chemically induced ; Heart Diseases/epidemiology ; Humans ; Hydroxychloroquine/adverse effects ; Hydroxychloroquine/therapeutic use ; Incidence ; Pandemics ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/epidemiology ; SARS-CoV-2
    Chemical Substances Hydroxychloroquine (4QWG6N8QKH) ; Chloroquine (886U3H6UFF)
    Keywords covid19
    Language English
    Publishing date 2020-05-28
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Review
    ZDB-ID 2653953-6
    ISSN 2047-9980 ; 2047-9980
    ISSN (online) 2047-9980
    ISSN 2047-9980
    DOI 10.1161/JAHA.120.016887
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Chloroquine, hydroxychloroquine and COVID-19.

    Erickson, T B / Chai, P R / Boyer, E W

    Toxicology communications

    2020  Volume 4, Issue 1, Page(s) 40–42

    Abstract: The media have featured the antimalarials chloroquine (CQ) and hydroxychloroquine (HCQ) to treat ... prolongation. CQ may also cause seizures, often refractory to standard treatment. Of concern is pediatric ... coronavirus (COVID-19). Political leaders have touted their use and recommended availability to the public ...

    Abstract The media have featured the antimalarials chloroquine (CQ) and hydroxychloroquine (HCQ) to treat coronavirus (COVID-19). Political leaders have touted their use and recommended availability to the public. These anti-inflammatory agents have substantial human toxicity with a narrow therapeutic window. CQ and HCQ poisoning cause myocardial depression and profound hypotension due to vasodilation. Bradycardia and ventricular escape rhythms arise from impaired myocardial automaticity and conductivity due to sodium and potassium channel blockade. With cardiotoxicity, ECGs may show widened QRS, atrioventricular heart block and QT interval prolongation. CQ may also cause seizures, often refractory to standard treatment. Of concern is pediatric poisoning, where 1-2 pills of CQ or HCQ can cause serious and potentially fatal toxicity in a toddler. The treatment of CQ/HCQ poisoning includes high-dose intravenous diazepam postulated to have positive ionotropic and antidysrhythmic properties that may antagonize the cardiotoxic effects of CQ. Infusions of epinephrine titrated to treat unstable hypotension, as well as potassium for severe hypokalemia may be required. Current scientific evidence does not support treatment or prophylactic use of these agents for COVID-19 disease. Regulatory and public health authorities recognize that CQ/HCQ may offer little clinical benefit and only add risk requiring further investigation before wider public distribution.
    Keywords covid19
    Language English
    Publishing date 2020-04-30
    Publishing country England
    Document type Journal Article
    ISSN 2473-4306
    ISSN (online) 2473-4306
    DOI 10.1080/24734306.2020.1757967
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Chloroquine, hydroxychloroquine and COVID-19

    Erickson, Timothy / Chai, P. R. / Boyer, E. W.

    Toxicology Communications, 4(1):40-42

    2020  

    Abstract: The media have featured the antimalarials chloroquine (CQ) and hydroxychloroquine (HCQ) to treat ... prolongation. CQ may also cause seizures, often refractory to standard treatment. Of concern is pediatric ... coronavirus (COVID-19). Political leaders have touted their use and recommended availability to the public ...

    Abstract The media have featured the antimalarials chloroquine (CQ) and hydroxychloroquine (HCQ) to treat coronavirus (COVID-19). Political leaders have touted their use and recommended availability to the public. These anti-inflammatory agents have substantial human toxicity with a narrow therapeutic window. CQ and HCQ poisoning cause myocardial depression and profound hypotension due to vasodilation. Bradycardia and ventricular escape rhythms arise from impaired myocardial automaticity and conductivity due to sodium and potassium channel blockade. With cardiotoxicity, ECGs may show widened QRS, atrioventricular heart block and QT interval prolongation. CQ may also cause seizures, often refractory to standard treatment. Of concern is pediatric poisoning, where 1-2 pills of CQ or HCQ can cause serious and potentially fatal toxicity in a toddler. The treatment of CQ/HCQ poisoning includes high-dose intravenous diazepam postulated to have positive ionotropic and antidysrhythmic properties that may antagonize the cardiotoxic effects of CQ. Infusions of epinephrine titrated to treat unstable hypotension, as well as potassium for severe hypokalemia may be required. Current scientific evidence does not support treatment or prophylactic use of these agents for COVID-19 disease. Regulatory and public health authorities recognize that CQ/HCQ may offer little clinical benefit and only add risk requiring further investigation before wider public distribution.
    Keywords COVID-19 ; epinephrine ; Chloroquine ; diazepam ; coronavirus ; hydroxychloroquine ; covid19
    Language English
    Publishing country de
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  4. Article: Chloroquine, hydroxychloroquine and COVID-19

    Erickson, T. B. / Chai, P. R. / Boyer, E. W.

    Toxicol Commun

    Abstract: The media have featured the antimalarials chloroquine (CQ) and hydroxychloroquine (HCQ) to treat ... prolongation CQ may also cause seizures, often refractory to standard treatment Of concern is pediatric ... coronavirus (COVID-19) Political leaders have touted their use and recommended availability to the public ...

    Abstract The media have featured the antimalarials chloroquine (CQ) and hydroxychloroquine (HCQ) to treat coronavirus (COVID-19) Political leaders have touted their use and recommended availability to the public These anti-inflammatory agents have substantial human toxicity with a narrow therapeutic window CQ and HCQ poisoning cause myocardial depression and profound hypotension due to vasodilation Bradycardia and ventricular escape rhythms arise from impaired myocardial automaticity and conductivity due to sodium and potassium channel blockade With cardiotoxicity, ECGs may show widened QRS, atrioventricular heart block and QT interval prolongation CQ may also cause seizures, often refractory to standard treatment Of concern is pediatric poisoning, where 1-2 pills of CQ or HCQ can cause serious and potentially fatal toxicity in a toddler The treatment of CQ/HCQ poisoning includes high-dose intravenous diazepam postulated to have positive ionotropic and antidysrhythmic properties that may antagonize the cardiotoxic effects of CQ Infusions of epinephrine titrated to treat unstable hypotension, as well as potassium for severe hypokalemia may be required Current scientific evidence does not support treatment or prophylactic use of these agents for COVID-19 disease Regulatory and public health authorities recognize that CQ/HCQ may offer little clinical benefit and only add risk requiring further investigation before wider public distribution
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #405356
    Database COVID19

    Kategorien

  5. Article ; Online: Chloroquine, hydroxychloroquine and COVID-19

    Erickson, T. B. / Chai, P. R. / Boyer, E. W.

    PMC

    2020  

    Abstract: The media have featured the antimalarials chloroquine (CQ) and hydroxychloroquine (HCQ) to treat ... prolongation. CQ may also cause seizures, often refractory to standard treatment. Of concern is pediatric ... coronavirus (COVID-19). Political leaders have touted their use and recommended availability to the public ...

    Abstract The media have featured the antimalarials chloroquine (CQ) and hydroxychloroquine (HCQ) to treat coronavirus (COVID-19). Political leaders have touted their use and recommended availability to the public. These anti-inflammatory agents have substantial human toxicity with a narrow therapeutic window. CQ and HCQ poisoning cause myocardial depression and profound hypotension due to vasodilation. Bradycardia and ventricular escape rhythms arise from impaired myocardial automaticity and conductivity due to sodium and potassium channel blockade. With cardiotoxicity, ECGs may show widened QRS, atrioventricular heart block and QT interval prolongation. CQ may also cause seizures, often refractory to standard treatment. Of concern is pediatric poisoning, where 1-2 pills of CQ or HCQ can cause serious and potentially fatal toxicity in a toddler. The treatment of CQ/HCQ poisoning includes high-dose intravenous diazepam postulated to have positive ionotropic and antidysrhythmic properties that may antagonize the cardiotoxic effects of CQ. Infusions of epinephrine titrated to treat unstable hypotension, as well as potassium for severe hypokalemia may be required. Current scientific evidence does not support treatment or prophylactic use of these agents for COVID-19 disease. Regulatory and public health authorities recognize that CQ/HCQ may offer little clinical benefit and only add risk requiring further investigation before wider public distribution.

    National Institutes of Health (Grant K23DA044874)
    Keywords covid19
    Publisher Informa UK Limited
    Publishing country us
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  6. Article ; Online: Chloroquine or Hydroxychloroquine for COVID19

    Kamp, Timothy J. / Hamdan, Mohamed H. / January, Craig T.

    Journal of the American Heart Association

    Is Cardiotoxicity a Concern?

    2020  Volume 9, Issue 12

    Keywords Cardiology and Cardiovascular Medicine ; covid19
    Language English
    Publisher Ovid Technologies (Wolters Kluwer Health)
    Publishing country us
    Document type Article ; Online
    ZDB-ID 2653953-6
    ISSN 2047-9980
    ISSN 2047-9980
    DOI 10.1161/jaha.120.016887
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  7. Article ; Online: Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose.

    Doyno, Cassandra / Sobieraj, Diana M / Baker, William L

    Clinical toxicology (Philadelphia, Pa.)

    2020  Volume 59, Issue 1, Page(s) 12–23

    Abstract: ... Cardiotoxicity became of increased concern with its use in COVID-19 patients. Long-term (years) toxicities ... years, hydroxychloroquine is now used to treat conditions such as rheumatoid arthritis and systemic ... Hydroxychloroquine is a generally well-tolerated medication. Short-term (days to weeks) toxicity includes ...

    Abstract Introduction: While chloroquine, a derivative of quinine, has been used as an antimalarial for 70 years, hydroxychloroquine is now used to treat conditions such as rheumatoid arthritis and systemic lupus erythematosus. In 2020, hydroxychloroquine (and to a lesser extent chloroquine) also received attention as a possible treatment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). During investigation for treating coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2, concerns for serious adverse events arose.
    Objective: We review the toxicity associated with hydroxychloroquine and chloroquine use both short-term and long-term and in overdose.
    Methods: Medline (
    Toxicity with short-term use: Gastrointestinal
    Toxicity with long-term use: Retinopathy
    Toxicity in overdose: Symptoms in overdose manifest rapidly (minutes to hours) and cardiotoxicity such as cardiovascular shock and collapse are most prominent. Neurotoxic effects such as psychosis and seizure may also occur.
    Conclusions: Hydroxychloroquine is a generally well-tolerated medication. Short-term (days to weeks) toxicity includes gastrointestinal effects and rarely glucose abnormalities, dermatologic reactions, and neuropsychiatric events. Cardiotoxicity became of increased concern with its use in COVID-19 patients. Long-term (years) toxicities include retinopathy, neuromyotoxicity, and cardiotoxicity (conduction abnormalities, cardiomyopathy). Deaths from overdoses most often result from cardiovascular collapse.
    MeSH term(s) Blood Glucose/analysis ; COVID-19/drug therapy ; Cardiotoxicity ; Chloroquine/toxicity ; Drug Overdose/etiology ; Gastrointestinal Diseases/chemically induced ; Humans ; Hydroxychloroquine/toxicity ; Psychoses, Substance-Induced/etiology ; Retinal Diseases/chemically induced ; SARS-CoV-2 ; Skin Diseases/chemically induced
    Chemical Substances Blood Glucose ; Hydroxychloroquine (4QWG6N8QKH) ; Chloroquine (886U3H6UFF)
    Keywords covid19
    Language English
    Publishing date 2020-09-22
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 204476-6
    ISSN 1556-9519 ; 0009-9309 ; 0731-3810 ; 1556-3650
    ISSN (online) 1556-9519
    ISSN 0009-9309 ; 0731-3810 ; 1556-3650
    DOI 10.1080/15563650.2020.1817479
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose

    Doyno, Cassandra / Sobieraj, Diana M / Baker, William L

    Clin Toxicol (Phila)

    Abstract: ... with hydroxychloroquine or chloroquine with COVID-19, we searched PubMed on June 10th, 2020: ("Chloroquine" or ... Hydroxychloroquine") AND ("Coronavirus" or "COVID-19" or "SARS-CoV-2"). This search resulted in 638 articles ... through June 7 2020 using the following as either MeSH or keyword terms: ("Chloroquine/" or "Hydroxychloroquine ...

    Abstract INTRODUCTION: While chloroquine, a derivative of quinine, has been used as an antimalarial for 70 years, hydroxychloroquine is now used to treat conditions such as rheumatoid arthritis and systemic lupus erythematosus. In 2020, hydroxychloroquine (and to a lesser extent chloroquine) also received attention as a possible treatment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). During investigation for treating coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2, concerns for serious adverse events arose. OBJECTIVE: We review the toxicity associated with hydroxychloroquine and chloroquine use both short-term and long-term and in overdose. METHODS: Medline (via OVID) was searched from its inception through June 7 2020 using the following as either MeSH or keyword terms: ("Chloroquine/" or "Hydroxychloroquine/") AND ("Adverse Drug Event/" or "Toxicities, Drug/" or "Toxic.mp." or "Toxicity.mp." or "Overdose.mp."). We limited resultant articles to those published in English and reporting on Human subjects. This search yielded 330 articles, of which 57 were included. Articles were excluded due to lack of relevance, not reporting desired outcomes, or being duplicative in their content. Twenty-five additional articles were identified through screening references of included articles. To identify toxicities in individuals treated with hydroxychloroquine or chloroquine with COVID-19, we searched PubMed on June 10th, 2020: ("Chloroquine" or "Hydroxychloroquine") AND ("Coronavirus" or "COVID-19" or "SARS-CoV-2"). This search resulted in 638 articles. We reviewed articles for reporting of adverse events or toxicities. Most citations were excluded because they did not include original investigations or extrapolated data from subjects that did not have COVID-19; 34 citations were relevant. For the drug-interactions section, relevant classes and agents were identified through a screen of the https://www.covid19-druginteractions.org/ website. We then conducted targeted searches of PubMed up to June 7th 2020 combining "chloroquine" and "hydroxychloroquine" with terms for specific drug classes and drugs identified from the drug-interaction site as potentially relevant. We found 29 relevant articles. TOXICITY WITH SHORT-TERM USE: Gastrointestinal: Gastrointestinal toxicities are the most common to occur following initiation of chloroquine or hydroxychloroquine. Nausea, vomiting, and diarrhea account for most reported intolerances. Glucose abnormalities: Alterations in blood glucose concentrations may occur with hydroxychloroquine but are rare with standard therapeutic use. Cardiotoxicity: Short-term use can produce conduction abnormalities. Evidence from COVID-19 treatment suggests QT/QTc prolongation is of concern, particularly when used in combination with azithromycin, although disagreement exists across studies. Dermatologic: Drug eruptions or rashes, followed by cutaneous hyperpigmentation, pruritis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, may occur within days to weeks of exposure but usually resolve with the discontinuation of therapy. Neuropsychiatric: Reported symptoms include confusion, disorientation, and hallucination within 24-48 h of drug initiation. Other toxicities: Hemolysis and anemia may occur in patients with glucose-6-phosphate dehydrogenase. Chloroquine treatment of COVID-19 was associated with elevation in creatine kinase and creatine kinase-MB activities with more events in the higher-dose group. TOXICITY WITH LONG-TERM USE: Retinopathy: Retinopathy is the major dose-limiting toxicity associated with long-term use; the risk is higher with increasing age, dose, and duration of usage. Cardiotoxicity: Long-term use has been associated with conduction abnormalities, cardiomyopathy, and valvular disorders. Neurotoxicity: Rarely myositis and muscle weakness, extremity weakness, and pseudoparkinsonism have been reported. TOXICITY IN OVERDOSE: Symptoms in overdose manifest rapidly (minutes to hours) and cardiotoxicity such as cardiovascular shock and collapse are most prominent. Neurotoxic effects such as psychosis and seizure may also occur. CONCLUSIONS: Hydroxychloroquine is a generally well-tolerated medication. Short-term (days to weeks) toxicity includes gastrointestinal effects and rarely glucose abnormalities, dermatologic reactions, and neuropsychiatric events. Cardiotoxicity became of increased concern with its use in COVID-19 patients. Long-term (years) toxicities include retinopathy, neuromyotoxicity, and cardiotoxicity (conduction abnormalities, cardiomyopathy). Deaths from overdoses most often result from cardiovascular collapse.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #786943
    Database COVID19

    Kategorien

  9. Article ; Online: Hydroxychloroquine Attenuates hERG Channel by Promoting the Membrane Channel Degradation: Computational Simulation and Experimental Evidence for QT-Interval Prolongation with Hydroxychloroquine Treatment.

    Wang, Xiqiang / Feng, Yunfei / Liu, Senmiao / Liu, Jing / Pan, Shuo / Wei, Linyan / Ma, Yanpeng / Liu, Zhongwei / Xing, Yujie / Wang, Junkui / Cui, Qianwei / Zhang, Yong / Wang, Tingzhong / Cai, Chuipu

    Cardiology

    2023  Volume 148, Issue 4, Page(s) 310–323

    Abstract: ... in the COVID-19 clinical trials, and full evaluation of their cardiotoxicity risks is in high demand ... Methods: We mainly focused on hydroxychloroquine (HCQ), one of the most concerned drugs for COVID-19 ... Introduction: The coronavirus disease 2019 (COVID-19) pandemic has led to millions of confirmed ...

    Abstract Introduction: The coronavirus disease 2019 (COVID-19) pandemic has led to millions of confirmed cases and deaths worldwide and has no approved therapy. Currently, more than 700 drugs are tested in the COVID-19 clinical trials, and full evaluation of their cardiotoxicity risks is in high demand.
    Methods: We mainly focused on hydroxychloroquine (HCQ), one of the most concerned drugs for COVID-19 therapy, and investigated the effects and underlying mechanisms of HCQ on hERG channel via molecular docking simulations. We further applied the HEK293 cell line stably expressing hERG-wild-type channel (hERG-HEK) and HEK293 cells transiently expressing hERG-p.Y652A or hERG-p.F656A mutants to validate our predictions. Western blot analysis was used to determine the hERG channel, and the whole-cell patch clamp was utilized to record hERG current (IhERG).
    Results: HCQ reduced the mature hERG protein in a time- and concentration-dependent manner. Correspondingly, chronic and acute treatment of HCQ decreased the hERG current. Treatment with brefeldin A (BFA) and HCQ combination reduced hERG protein to a greater extent than BFA alone. Moreover, disruption of the typical hERG binding site (hERG-p.Y652A or hERG-p.F656A) rescued HCQ-mediated hERG protein and IhERG reduction.
    Conclusion: HCQ can reduce the mature hERG channel expression and IhERG via enhancing channel degradation. The QT prolongation effect of HCQ is mediated by typical hERG binding sites involving residues Tyr652 and Phe656.
    MeSH term(s) Humans ; COVID-19 ; COVID-19 Drug Treatment ; ERG1 Potassium Channel/genetics ; Ether-A-Go-Go Potassium Channels/chemistry ; Ether-A-Go-Go Potassium Channels/genetics ; Ether-A-Go-Go Potassium Channels/metabolism ; HEK293 Cells ; Hydroxychloroquine/pharmacology ; Ion Channels ; Molecular Docking Simulation ; Mutation
    Chemical Substances ERG1 Potassium Channel ; Ether-A-Go-Go Potassium Channels ; Hydroxychloroquine (4QWG6N8QKH) ; Ion Channels ; KCNH2 protein, human
    Language English
    Publishing date 2023-05-22
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 80092-2
    ISSN 1421-9751 ; 0008-6312
    ISSN (online) 1421-9751
    ISSN 0008-6312
    DOI 10.1159/000531132
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top